BRAF^(V600E)突变性中低危甲状腺乳头状癌患者^(131)I治疗疗效评价  

Clinical Outcome of Radioiodine Therapy in Low-intermediate Risk Papillary Thyroid Carcinoma with BRAF^(V600E) Mutation

作　　者：李娇[1] 杨涛[2] 赵腾[1] 梁军[1] 林岩松[2] LI Jiao YANG Tao ZHAO Teng LIANG Jun LIN Yan-song(Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, China Department of Nuclear Medicine, PUMC Hospital, CAMS and PUMC, Beijing 100730, China)

机构地区：[1]青岛大学附属医院肿瘤科,山东青岛266003 [2]中国医科院学院北京协和医学院北京协和医院核医学科,北京100730

出　　处：《中国医学科学院学报》2016年第3期346-350,共5页Acta Academiae Medicinae Sinicae

基　　金：国家自然科学基金(30970850);卫生部行业科研专项项目(201202012)~~

摘　　要：目的评估BRAFV600E基因状态对中低危复发风险甲状腺乳头状癌(PTC)患者131I清甲治疗疗效的影响。方法将135例中低危复发风险PTC患者根据BRAFV600E基因状态分为BRAFV600E突变组(n=105)和BRAFV600E野生组(n=30)两组,所有患者均经双侧甲状腺全切及131I清甲治疗后规律随访,中位随访时间2.16年(1.03~4.06年),根据131I治疗后血清学及影像学随诊结果将其临床转归分为疗效满意(ER)、疗效尚可(AR)和疗效不满意(IR),分别比较两组患者经131I清甲治疗后的临床转归情况。结果两组患者的临床病理基线资料及131I治疗剂量差异均无统计学意义(P均>0.05)。BRAFV600E突变组经131I清甲治疗后ER、AR、IR分别为74.3%、20.0%、5.7%,与BRAFV600E野生组的73.3%、20.0%、6.7%差异无统计学意义(P=0.891)。结论对于术后中低危复发风险的PTC患者,BRAFV600E基因突变与否可能不影响其131I清甲疗效,该分子特征不应一概作为中低危人群风险评估中的独立权重因素。Objective To evaluate the impact of BRAFV600E gene status on clinical outcome of radioio- dine （131 I） therapy in low-intermediate risk recurrent papillary thyroid carcinoma （PTC） . Methods Totally 135 PTC patients were enrolled and divided into two groups according to BRAFV600Egene status ： BRAFV600E muta- tion group （n = 105） and BRAFV600E wild group （n =30） . The median follow-up time was 2. 16 years （ 1.03- 4. 06 years）, and clinical outcome after initial 131I ablation therapy was divided into excellent response （ER）, acceptable response （AR）, and incomplete response （IR） according to the serological and imageological fol- low-up results. The cinical outcomes were then compared between these two groups. Results nificant difference in clinicopathological features and initial radioactive iodine dose between There was no sig- BRAFV600E mutation and wild groups （P 〉0.05） . ER, AR, and IR after 131I ablation therapy accounted for 74. 3%, 20. 0%, and 5.7% in BRAFV600E mutation group and 73.3% , 20. 0%, and 6. 7% in BRAFV600E wild group, and no sta- tistical difference was found （P = 0. 891 ） . Conclusion For low-intermediate risk recurrent PTC, BRAFV600E gene status may have no impact on the response to 131I ablation therapy, and thus this molecular feature should not be used as an independent weighting factor for risk assessment in this population.

关 键 词：甲状腺乳头状癌 BRAFV600E基因 131I治疗 临床转归 

分 类 号：R736.1[医药卫生—肿瘤]